Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Tekla Capital Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
Tekla Capital Management

Tekla Capital Management

Operating

Tekla Capital Management: Boston-based adviser for healthcare and life sciences equity funds.

Location
Boston, MA, US
Founded
1986
Firm
Compare
Portfolio
Employees
Website

Investments

Invetx
Invetx

Total Raised

$85.8M

Rounds

3

Series B$60.5MMay 2022
Series A$10.3MSeptember 2020
Arkuda Therapeutics
Arkuda Therapeutics

Total Raised

$108M

Rounds

3

Series B$64MFebruary 2022
Series A$44MNovember 2019
Endeavor Biomedicines
Endeavor Biomedicines

Total Raised

$163M

Rounds

2

Series B$101MFebruary 2022
Arbor Biotechnologies
Arbor Biotechnologies

Total Raised

$230.6M

Rounds

2

Series B$215MNovember 2021
Parthenon Therapeutics
Parthenon Therapeutics

Total Raised

$65M

Rounds

1

Series A$65MNovember 2021
ReCode Therapeutics
ReCode Therapeutics

Total Raised

$521.8M

Rounds

6

Series B$259.8MOctober 2021
Aristea Therapeutics
Aristea Therapeutics

Total Raised

$117.6M

Rounds

3

Series B$63MJuly 2021
ImmuneID
ImmuneID

Total Raised

$67M

Rounds

2

Series A$50MJune 2021
Biotheryx
Biotheryx
Public

Total Raised

$134.7M

Rounds

6

Series E$92MMay 2021
Caribou Biosciences
Caribou Biosciences
Public

Total Raised

$317.7M

Rounds

9

Series C$115MMarch 2021
HotSpot Therapeutics
HotSpot Therapeutics

Total Raised

$210M

Rounds

4

Series B$65MMay 2020
Amphivena Therapeutics
Amphivena Therapeutics

Total Raised

$135.7M

Rounds

5

Series C$62MSeptember 2019
CuraSen Therapeutics
CuraSen Therapeutics

Total Raised

$95.9M

Rounds

5

Series A$54.5MOctober 2018
Sutro Biopharma
Sutro Biopharma
Public

Total Raised

$561.6M

Rounds

12

Series E$85.4MJuly 2018
Rainier Therapeutics
Rainier Therapeutics

Total Raised

$89M

Rounds

5

Series B$20MMay 2018
Series B$30MMarch 2017
Series A$13MJanuary 2016
Ovid Therapeutics
Ovid Therapeutics
Public

Total Raised

$184.1M

Rounds

7

Series B$75MAugust 2015
CytomX Therapeutics
CytomX Therapeutics
Public

Total Raised

$345.4M

Rounds

9

Series D$70MJune 2015
Insightra Medical
Insightra Medical

Total Raised

$20M

Rounds

5

Series COctober 2013
Cardiokinetix
Cardiokinetix
Acquired

Total Raised

$112.5M

Rounds

6

Series E$23MMarch 2013
Puma Biotechnology
Puma Biotechnology
Public

Total Raised

$809.3M

Rounds

8

Post Ipo Equity$55MOctober 2011